AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

4.5M

Current Price

$0.12
0.00 (0.00%)

Book Price

$-0.26
Overvalued by 318.89%
Financial Institution

Company Metrics

  • 1.46 P/E
  • 107.12 P/S
  • 0.87 P/B
  • 0.082 EPS
  • 0 / 0% Dividend
  • 210,166.00 Avg. Vol.
  • 37.50M Shares
  • 4.5M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Affymax, Inc. (NASDAQ:AFFY) Posts Huge Gains On Heavy Volume
Argyll Free Press - Sep 28, 2014
Stocks to watch Affymax, Inc. (NASDAQ:AFFY) rose 32.5 percent to $2.08 with 32,487,200 shares traded on Friday. Affymax, Inc. is a biopharmaceutical company that develops drugs to improve the treatment of serious and often life-threatening conditions.
Xstelos Announces Intention To Vote Against Affymax's Plan Of Liquidation At ...
Stockhouse - Sep 19, 2014
NEW YORK, Sept. 19, 2014 /PRNewswire/ -- Xstelos Holdings, Inc. and the members of its Schedule 13D group (collectively, the "Xstelos Group" or "we") own approximately 5.0% of the outstanding shares of common stock of Affymax, Inc. (OTC: AFFY) ...
AuraSense Therapeutics Welcomes Key Personnel, Further Expanding ...
MarketWatch - Oct 1, 2014
Ms. Kim's additional industry experience includes executive positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation. In addition to her industry experience, Ms. Kim also served as chief program officer for the Gordon and ...
Affymax board announces decision to dissolve the company
Reuters Key Development - Jun 24, 2014